These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12145841)

  • 1. [Current drugs. New clinical problems].
    Ferrand I
    Bull Acad Natl Med; 2002; 186(2):339-44. PubMed ID: 12145841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial: ocular effects of criminal drug use.
    Firth AY
    Can J Ophthalmol; 2006 Apr; 41(2):140-6. PubMed ID: 16767200
    [No Abstract]   [Full Text] [Related]  

  • 3. Club Drugs: What You Should Know.
    Am Fam Physician; 2018 Jul; 98(2):Online. PubMed ID: 30216001
    [No Abstract]   [Full Text] [Related]  

  • 4. Cognitive deficits and cognitive normality in recreational cannabis and Ecstasy/MDMA users.
    Parrott A
    Hum Psychopharmacol; 2003 Mar; 18(2):89-90. PubMed ID: 12590401
    [No Abstract]   [Full Text] [Related]  

  • 5. [Has ecstasy neurotoxic effects in humans?].
    Rosenberg R
    Ugeskr Laeger; 1999 Dec; 161(50):6941. PubMed ID: 10643384
    [No Abstract]   [Full Text] [Related]  

  • 6. [Street narcotics].
    Kaa E; Müller IB; Rollmann D
    Ugeskr Laeger; 2003 Sep; 165(38):3633-4. PubMed ID: 14556400
    [No Abstract]   [Full Text] [Related]  

  • 7. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
    de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R
    J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Club drugs: reasons for and consequences of use.
    Parks KA; Kennedy CL
    J Psychoactive Drugs; 2004 Sep; 36(3):295-302. PubMed ID: 15559677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rave drugs: pharmacological considerations.
    Klein M; Kramer F
    AANA J; 2004 Feb; 72(1):61-7. PubMed ID: 15098519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Public health. Rave review.
    Salt P
    Nurs Times; 1993 Dec 15-21; 89(50):36-8. PubMed ID: 7904059
    [No Abstract]   [Full Text] [Related]  

  • 11. Everyday memory deficits in ecstasy-polydrug users.
    Montgomery C; Fisk JE
    J Psychopharmacol; 2007 Sep; 21(7):709-17. PubMed ID: 17606476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathways into ecstasy use: the role of prior cannabis use and ecstasy availability.
    Zimmermann P; Wittchen HU; Waszak F; Nocon A; Höfler M; Lieb R
    Drug Alcohol Depend; 2005 Sep; 79(3):331-41. PubMed ID: 15913921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recreational drug misuse: issues for the cardiologist.
    Ghuran A; Nolan J
    Heart; 2000 Jun; 83(6):627-33. PubMed ID: 10814617
    [No Abstract]   [Full Text] [Related]  

  • 14. [Paramethoxymethamphetamine].
    Westin AA; Brede WR
    Tidsskr Nor Laegeforen; 2011 Oct; 131(20):2008. PubMed ID: 22016127
    [No Abstract]   [Full Text] [Related]  

  • 15. Ecstasy (MDMA) and memory function: a meta-analytic update.
    Laws KR; Kokkalis J
    Hum Psychopharmacol; 2007 Aug; 22(6):381-8. PubMed ID: 17621368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal methamphetamine smoking among regular ecstasy users in Australia: increases in use and associations with harm.
    Kinner SA; Degenhardt L
    Drug Alcohol Rev; 2008 May; 27(3):292-300. PubMed ID: 18368611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. More about parkinsonism after taking ecstasy.
    Sewell RA; Cozzi NV
    N Engl J Med; 1999 Oct; 341(18):1400; author reply 1401. PubMed ID: 10577096
    [No Abstract]   [Full Text] [Related]  

  • 18. The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine.
    Karlsen SN; Spigset O; Slørdal L
    Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):15-24. PubMed ID: 18047478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Emergencies associated with the consumption of designer drugs, hallucinogens and amphetamines treated at 15 Spanish hospitals in 1994. Work Group on the Study of Emergencies due to Psychostimulants].
    Rodríguez Arenas MA; Barrio Anta G; de la Fuente de Hoz L; Royuela L
    Rev Clin Esp; 1997 Dec; 197(12):804-9. PubMed ID: 9477670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A brief overview of the clinical pharmacology of "club drugs".
    Britt GC; McCance-Katz EF
    Subst Use Misuse; 2005; 40(9-10):1189-201. PubMed ID: 16048813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.